Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,214,743
  • Shares Outstanding, K 687,560
  • Annual Sales, $ 7,135 M
  • Annual Income, $ 131,340 K
  • 60-Month Beta 0.57
  • Price/Sales 0.57
  • Price/Cash Flow 7.30
  • Price/Book 0.46
Trade GRFS with:

Options Overview Details

View History
  • Implied Volatility 105.32% ( +15.76%)
  • Historical Volatility 111.88%
  • IV Percentile 90%
  • IV Rank 58.68%
  • IV High 166.84% on 03/07/24
  • IV Low 17.95% on 12/01/23
  • Put/Call Vol Ratio 0.77
  • Today's Volume 312
  • Volume Avg (30-Day) 6,038
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 67,077
  • Open Int (30-Day) 52,634

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.30 +14.15%
on 03/06/24
9.37 -35.43%
on 02/28/24
-2.42 (-28.57%)
since 02/16/24
3-Month
5.30 +14.15%
on 03/06/24
12.15 -50.21%
on 12/29/23
-4.03 (-39.98%)
since 12/18/23
52-Week
5.30 +14.15%
on 03/06/24
12.15 -50.21%
on 12/29/23
-0.66 (-9.84%)
since 03/17/23

Most Recent Stories

More News
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain

/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...

GRFS : 6.05 (-1.31%)
Why Shares of Grifols Were Up Tuesday

The company gave first-quarter numbers.

GRFS : 6.05 (-1.31%)
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...

GRF : 9.47 (+2.16%)
GRFS : 6.05 (-1.31%)
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Sector ETF report for FBT

FBT : 151.35 (-0.24%)
MRNA : 104.26 (+0.39%)
IBB : 135.26 (-0.49%)
GRFS : 6.05 (-1.31%)
EXAS : 58.86 (+1.99%)
XBI : 92.95 (-1.86%)
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

FBT : 151.35 (-0.24%)
MRNA : 104.26 (+0.39%)
IBB : 135.26 (-0.49%)
GRFS : 6.05 (-1.31%)
EXAS : 58.86 (+1.99%)
XBI : 92.95 (-1.86%)
Are Investors Undervaluing Grifols (GRFS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

GRFS : 6.05 (-1.31%)
Grifols (GRFS) Upgraded to Strong Buy: Here's Why

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GRFS : 6.05 (-1.31%)
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease

/PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research,...

GRFS : 6.05 (-1.31%)
Is Grifols (GRFS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

GRFS : 6.05 (-1.31%)
TAK : 14.56 (+0.62%)
Is Grifols (GRFS) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

GRFS : 6.05 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

3rd Resistance Point 6.24
2nd Resistance Point 6.16
1st Resistance Point 6.10
Last Price 6.05
1st Support Level 5.96
2nd Support Level 5.88
3rd Support Level 5.82

See More

52-Week High 12.15
Fibonacci 61.8% 9.53
Fibonacci 50% 8.73
Fibonacci 38.2% 7.92
Last Price 6.05
52-Week Low 5.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar